# Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel

> **NCT00705835** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** rsPSMA protein plus Alhydrogel® vaccine

## Key facts

- **NCT ID:** NCT00705835
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2012-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00705835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00705835, "Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00705835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*